Study S000986

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02404376
Acronym: COMBAT-MI
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 378
Start: 2016-03
Primary completion: 2019-08
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
Conditions: ST Elevation Acute Myocardial Infarction
Interventions: DRUG:Exenatide; OTHER:Remote Ischemic Conditioning (RIC); DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Myocardial Infarct Size [3-7 days after pPCI]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023502	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Lønborg J, European heart journal	2012	Randomized trial	PMID 21920963 DOI	registry reference BACKGROUND:21920963